HCW Biologics Inc. (HCWB)

HCW Biologics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	0.74	1.95	4.67	3.6	22.33	11.73
Short-Term Investments	-	-	-	-	9.74	24.98
Cash & Short-Term Investments	0.74	1.95	4.67	3.6	32.06	36.71
Cash Growth	-69.60%	-58.23%	30.03%	-88.79%	-12.67%	334.19%
Accounts Receivable	0.02	0.03	0.58	1.54	0.42	-
Other Receivables	-	-	-	-	-	0.13
Receivables	0.02	0.03	0.58	1.54	0.42	0.13
Prepaid Expenses	0.28	0.22	0.33	1.04	1.39	2.2
Other Current Assets	0.1	0.08	0.11	0.23	0.2	1.44
Total Current Assets	1.14	2.28	5.7	6.4	34.07	40.48
Property, Plant & Equipment	20.75	20.88	22.91	20.45	10.8	1.12
Long-Term Investments	4.85	1.33	1.6	1.6	1.6	11.52
Other Long-Term Assets	0.03	0.03	0.03	0.06	0.33	0.39
Total Assets	26.77	24.52	30.24	28.51	46.81	53.51

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	10.61	13.14	22.33	6.17	1.23	0.22
Accrued Expenses	1.13	1.1	0.95	2.43	1.55	0.3
Short-Term Debt	6.56	6.81	6.31	-	-	-
Current Portion of Long-Term Debt	-	-	-	0.12	-	-
Current Portion of Leases	-	-	-	0.03	0.18	-
Current Unearned Revenue	0.35	-	-	-	-	1.8
Other Current Liabilities	-	0.01	0.03	-	-	-
Total Current Liabilities	18.65	21.06	29.63	8.75	2.96	2.32
Long-Term Debt	-	-	7.38	6.3	6.41	-
Long-Term Leases	-	-	-	-	0.01	-
Other Long-Term Liabilities	0.69	0.69	-	-	-	-
Total Liabilities	19.34	21.76	37.01	15.05	9.38	2.32

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0	0	0	0	0	0
Additional Paid-In Capital	117.69	111.28	93.79	83.99	82.96	81.83
Retained Earnings	-110.26	-108.52	-100.56	-70.53	-45.54	-30.64
Total Common Equity	7.43	2.76	-6.77	13.46	37.43	51.19
Shareholders' Equity	7.43	2.76	-6.77	13.46	37.43	51.19
Total Liabilities & Equity	26.77	24.52	30.24	28.51	46.81	53.51

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	6.56	6.81	13.69	6.45	6.6	-
Net Cash (Debt)	-5.82	-4.86	-9.02	-2.86	25.46	36.71
Net Cash Growth	-	-	-	-	-30.65%	365.41%
Net Cash Per Share	-7.39	-13.89	-55.79	-19.08	170.58	469.42
Filing Date Shares Outstanding	1.84	1.12	0.19	0.16	0.15	0.15
Total Common Shares Outstanding	1.62	0.55	0.19	0.15	0.15	0.15
Working Capital	-17.51	-18.78	-23.93	-2.34	31.11	38.16
Book Value Per Share	4.59	5.06	-36.48	89.68	250.38	343.50
Tangible Book Value	7.43	2.76	-6.77	13.46	37.43	51.19
Tangible Book Value Per Share	4.59	5.06	-36.48	89.68	250.38	343.50
Land	-	2.15	2.15	2.15	2.15	-
Buildings	-	6.11	6.11	6.11	6.11	-
Machinery	-	2.66	2.66	2.66	2.62	2.42
Construction In Progress	-	12.02	13.55	10.44	0.05	-
Leasehold Improvements	-	0.35	0.35	0.35	0.35	0.35

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 14, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 9, 2026

Data Sources Report a data error